Arksarapuk Jittirat, MD
Nephrology · Cleveland, OHNPI 1770748147
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,000 of the $9,998 with a category attached, or 80.0%. Veloxis Pharmaceuticals, Inc. accounts for 78.0% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $8,871 and has fallen 96.0% since, to $359 in 2025. Among nephrology clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 33 payments — averaging $302.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Veloxis Pharmaceuticals, Inc.$8K
- AstraZeneca$1K
- Sanofi-aventis U.S. LLC$456
- Vifor Pharma, Inc.$244
- Mallinckrodt Hospital Products Inc.$135
- Calliditas Therapeutics US Inc.$97
- plus $214 from 7 others
Across 5 payments — averaging $12,639 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$41K
- CSL Behring$22K
What the payments were for
- Consulting fees$8,00080%
- Travel & lodging$3934%
- Food & beverage$1,45015%
- Education$1542%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 7 | $7,802 |
| AstraZeneca(2 entities) | 4 | $1,050 |
| Sanofi-aventis U.S. LLC | 4 | $456 |
| Vifor Pharma, Inc. | 8 | $244 |
| Mallinckrodt Hospital Products Inc. | 2 | $135 |
| Calliditas Therapeutics US Inc. | 1 | $97 |
| Fresenius USA Marketing, Inc. | 1 | $97 |
| Novartis | 1 | $24 |
| Merck | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Amgen | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Envarsus$7,653
- SOLIRIS$1,000
- THYMOGLOBULIN$356
- TERLIVAZ$122
How this compares
$9,998 in reported general payments places this provider in the 90th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 21 | $126,731 |
| LokelmaSodium Zirconium Cyclosilicate | 51 | $59,047 |
| FarxigaDapagliflozin Propanediol | 53 | $45,988 |
| Cinacalcet Hcl | 321 | $42,347 |
| Tacrolimus | 130 | $18,423 |
| Valganciclovir Hcl | 63 | $17,251 |
| JardianceEmpagliflozin | 29 | $16,746 |
| KerendiaFinerenone | 16 | $15,704 |
| EliquisApixaban | 20 | $15,565 |
| Mycophenolate Mofetil | 78 | $9,258 |
| RetacritEpoetin Alfa-Epbx | 18 | $7,246 |
| Envarsus XrTacrolimus | 16 | $5,990 |
| Sevelamer Carbonate | 42 | $5,366 |
| Clonidine | 17 | $4,971 |
| Prednisone | 953 | $4,234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $97 | $126,73121 claims |
| AstraZenecaLokelma, Farxiga | $1,050 | $105,034104 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 450 nephrology providers in Ohio.
Other nephrology in Cleveland
- Georges NakhoulCleveland$255K
- Sankar NavaneethanCleveland$253K
- Sevag DemirjianCleveland$158K
- Elias BassilCleveland$80K
- Ali MehdiCleveland$76K
- Amitkumar PatelCleveland$70K
- Emilio PoggioCleveland$41K
- Corey CavanaughCleveland$35K
- James SimonCleveland$29K
- Ziad ZakyCleveland$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.